February 2011
Retina Institute Japan, K.K. (currently HEALIOS K.K.) was established in Higashi-ku, Fukuoka City.
Discussions were initiated on strategies to commercialize RPE cell transplantation as a treatment for age-related macular degeneration.
December 2012
Tokyo office was opened in Chiyoda-ku, Tokyo.
February 2013
A patent licensing agreement was concluded with iPS Academia Japan, Inc. on iPS cell basic technology related to cellular therapy products containing RPE cells as an active ingredient.
March 2013
A patent licensing agreement was concluded with RIKEN, on RPE cells for the treatment of age-related macular degeneration.
September 2013
Business name was changed to HEALIOS K.K.
The Tokyo office and the main office were moved to Chuo-ku, Tokyo.
October 2013
Opening of our laboratory (currently the Kobe Research Institute) in Chuo-ku, Kobe.
December 2013
Agreement signed with Sumitomo Dainippon Pharma Co., Ltd. on the joint development in Japan of iPS cell–derived RPE cells for the treatment of age-related macular degeneration. A patent licensing agreement and a joint venture contract was also signed.
Ophthalmic viscoelastic preparation business was transferred from Aqumen Biopharmaceuticals K.K.
February 2014
Sighregen Co.,Ltd., a joint venture company with Sumitomo Dainippon Pharma Co., Ltd., was established.
September 2014
Main office was moved to Minato-ku, Tokyo.
October 2014
Start of collaborative research with Yokohama City University on cellular and tissue-based products using iPS and other cells.
June 2015
Listed on the Tokyo Stock Exchange market Mothers (code: 4593).
October 2015
Opening of Yokohama laboratory in Yokohama City University Advanced Medical Research Center
January 2016
A license agreement signed with Athersys, Inc. for the development and commercialization of novel cell therapy treatments, including MultiStem® for the treatment of ischemic stroke in Japan.
February 2017
A business and capital alliance agreement signed with Nikon Corporation in the field of regenerative medicine.
April 2017
Ophthalmic viscoelastic preparation business containing BBG250 was transferred to D. Western Therapeutics Institute, Inc.
February 2018
Establishment of Healios NA, Inc. in USA
May 2018
A collaborative research and development agreement signed with NEI
June 2018
Establishment of Organoid Neogenesis Laboratory Inc.
June 2019
Change in joint development framework with Sumitomo Dainippon Pharma in Japan for the treatment using iPSC-derived RPE cells.
July 2019
Expansion of business and capital alliance with Nikon in the field of regenerative medicine.
January 2020
Adoption of International Financial Reporting Standards (IFRS)
October 2020
Head office relocation to Tokyo Chiyoda-ku
January 2021
Establish ment of fund subsidiaries in the field of regenerative medicine. including Saisei Ventures LLC in the U.S.
August 2021
Sign of an agreement with Athersys to expand the overall scope of collaboration for commercialization.